Form 4: Jupiter Neurosciences CFO Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Jupiter Neurosciences CFO Saleem Elmasri was granted 525,565 stock options as part of a discretionary and long-term incentive plan.
Summary
- Saleem Elmasri, Chief Financial Officer of Jupiter Neurosciences, Inc., received a grant of 525,565 stock options.
- The grant consists of 325,565 options as a discretionary bonus for 2025 services and 200,000 options as long-term incentive compensation.
- The options have an exercise price of $0.2783 per share.
- The options vest over a three-year period starting September 2, 2026, in equal quarterly installments, contingent upon continued employment.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not materially alter the company's financial outlook.
Positives
- Aligns executive compensation with long-term shareholder interests through equity-based incentives.
- Retains key financial leadership through a multi-year vesting schedule.
Negatives
- Results in potential future dilution of existing shareholders upon the exercise of these options.
Risks
- Future dilution of equity if options are exercised.
- Dependence on continued employment for the vesting of the granted options.
Future Outlook
The options vest over three years in equal quarterly installments, indicating a focus on long-term retention and performance alignment for the CFO.
Management Comments
- The grant is structured as a mix of a discretionary bonus for 2025 services and long-term incentive compensation.
Industry Context
StockSavvy.ai notes that equity-based compensation is a standard practice in the biotechnology sector to preserve cash while incentivizing executive performance and retention.
Comparison to Industry Standards
- The use of a three-year vesting schedule is consistent with standard corporate governance practices for executive equity grants in small-cap biotech firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Grant of 525,565 options under the 2025 Equity Incentive Plan. | 06/02/2026 | Standard executive compensation adjustment. |
Stakeholder Impact
- Shareholders may experience minor dilution if options are exercised in the future.
Next Steps
- Vesting of options to commence on September 2, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/02/2026 | Date of the option grant transaction. |
| 09/02/2026 | Commencement date for the three-year vesting period. |
| 06/02/2036 | Expiration date of the granted stock options. |
Keywords
Jupiter Neurosciences, JUNS, Form 4, Stock Options, Executive Compensation, CFO, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.